Roche
Roche bags Siemens Healthcare coms head
March 25, 2010Medical Communications Roche, appointment, medical communications, sales and marketing
Roche has appointed Stephen Feldhaus as its new head of group communications to succeed Per-Olof Attinger (pictured left), who moves …
Roche delivers updated pipeline
March 18, 2010Cancer, Roche
Roche says its pipeline can sustain its growth in oncology and increase its presence in personalised healthcare. Roche also plans …
Roche cancer drug gets NICE thumbs up
March 5, 2010Sales and Marketing MabThera, Roche
NICE has recommended Roche’s MabThera to treat patients with the most common form of leukaemia, relapsed or refractory chronic lymphocytic …
NICE asks Roche for RoActemra cost data
March 5, 2010Sales and Marketing RoActemra, Roche
Roche’s attempts to secure NICE approval for rheumatoid arthritis drug RoActemra have hit another hurdle. NICE’s independent appraisal committee has …
Avastin fails in phase III study
February 24, 2010Research and Development Roche, avastin, gastric cancer, stomach cancer
Roche’s Avastin does not help patients with a severe form of stomach cancer to live longer, according to the results …
Roche diabetes trial proves promising
February 11, 2010Research and Development GLP-1, Roche, diabetes, taspoglutide
Phase III results for Roche’s once-weekly injectable drug taspoglutide have shown a positive effect on reducing blood glucose compared with …
Roche expands Herceptin franchise
February 8, 2010Sales and Marketing Herceptin, Roche, gastric cancer, stomach cancer
Roche’s blockbuster breast cancer treatment Herceptin has been launched in the UK as a treatment for stomach cancer. It is …
Genentech integration hits Roche profits
February 3, 2010Sales and Marketing 2009 financials, Genentech, Roche
Roche achieved healthy sales growth in 2009 but saw a 22% drop in net income due to the cost gaining …
Roche invests in production of new Herceptin formulation
January 25, 2010Manufacturing and Production, Research and Development Herceptin, Roche
Roche will spend 190 million Swiss francs ($183m) to put production capacity in place for a new self-administered formulation of …
Digital Pharma: Byte-sized roundup
January 15, 2010Medical Communications Diagnostics, Novartis, Roche, digital pharma, malaria
In this week’s roundup: Roche answers cancer testing questions, Novartis uses SMS in fight against malaria, UCB goes to Facebook …
FDA approves Roche’s Actemra
January 11, 2010Sales and Marketing Actemra, RoActemra, Roche, US, rheumatoid arthritis
Roche’s Actemra has been approved in the US for the treatment of moderately to severely active rheumatoid arthritis (RA) and …
Roche signs genetic chemistry technology deal
January 11, 2010Research and Development Evolva, Roche, genetic chemistry
Roche has signed a deal with Evolva Holding to create anti-infectives and cancer treatments using the latter’s genetic chemistry technology. Roche’s …
Roche plans striking new Basel offices
January 4, 2010Manufacturing and Production, Research and Development, Sales and Marketing Basel, Roche, construction
Roche has unveiled plans for its new main office building in Basel, Switzerland, that will accommodate more than 1,800 people …
Digital Pharma: Roche tackles sidewiki
December 21, 2009Medical Communications Roche, digi, digital pharma, google, sidewiki
Roche has become the second pharma company to tackle sidewiki on its corporate website, posting an entry that sets out …
NICE still saying ‘no’ to Roche’s RoActemra
December 17, 2009Sales and Marketing NICE, RoActemra, Roche
Roche will have to present a stronger case for arthritis drug RoActemra in order to gain approval, according to NICE. …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
